EUVIMEDEUVIMED entdecken
Crossref

Recurrent Revascularization at 10 Years After Percutaneous Treatment of Drug-Eluting Stent Restenosis

Tobias Koch, Tobias Lenz, Tobias Rheude, Salvatore Cassese, Mej Kazazi, Erion Xhepa, Thorsten Kessler, Jens Wiebe, Miroslaw Ferenc, Karl-Ludwig Laugwitz, Michael Joner, Heribert Schunkert und 2 weitere

JACC: Cardiovascular Interventions · 2024

DOI: 10.1016/j.jcin.2023.10.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Cardiovascular Interventions, 2024. Verfasst von Tobias Koch und 13 weiteren Autor:innen. Beteiligte Einrichtung: ISAResearch Zentrum, Deutsches Herzzentrum München, an der Technische Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Coronary Restenosis, Drug-Eluting Stents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Treatment of patients with recurrence of in-stent restenosis (ISR) remains particularly challenging, with data and guideline recommendations for repeat percutaneous coronary intervention being scant. OBJECTIVES: The aim of this study was to investigate the long-term incidence of recurrent revascularization events after percutaneous treatment of drug-eluting stent (DES) ISR. METHODS: In this post hoc analysis, 402 patients (500 lesions) assigned to plain balloon (PB), drug-coated balloon (DCB), or DES treatment in the randomized ISAR-DESIRE 3 (Efficacy Study of Paclitaxel-Eluting Balloon, -Stent vs. Plain Angioplasty for Drug-Eluting Stent Restenosis) trial were followed up over a median of 10.3 years. The primary endpoint was total repeat target lesion revascularization (R-TLR) including all, first and recurrent, events. RESULTS: At the end of follow-up, first R-TLR was required in 204 lesions, 82 in the PB group, 70 in the DCB group, and 52 in the DES group. The total number of R-TLRs was 373: 162 in the PB group, 124 in the DCB group, and 87 in the DES group. During the first year of follow-up, the risk for total R-TLR was reduced by DCB (HR: 0.36; 95% CI: 0.24-0.54) and DES (HR: 0.23; 95% CI: 0.14-0.38) treatment compared with PB treatment. After 1 year, the risk for total R-TLR was nonsignificantly reduced by DCB treatment (HR: 0.77; 95% CI: 0.51-1.16) and significantly reduced by DES treatment (HR: 0.61; 95% CI: 0.39-0.95) compared with PB treatment. Risk in the DCB and DES groups was similar during (HR: 1.54; 95% CI: 0.89-2.69) and after (HR: 1.26; 95% CI: 0.82-1.92) 1 year. CONCLUSIONS: The total number of R-TLRs over 10 years after treatment of patients with DES ISR was high. DCBs and particularly DES were able to reduce the need for both first and recurrent revascularization compared with PB treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary RestenosisDrug-Eluting StentsHumansAngioplasty, Balloon, CoronaryCoated Materials, BiocompatibleCoronary AngiographyPaclitaxelPercutaneous Coronary InterventionTreatment OutcomeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

DCBDESPBR-ISRdrug-coated balloondrug-eluting stentplain balloonrecurrent in-stent restenosis

Substanzen

Coated Materials, BiocompatiblePaclitaxel

Autor:innen und Institutionen

  • ISAResearch Zentrum, Deutsches Herzzentrum München, an der Technische Universität München, Munich, Germany.
  • ISAResearch Zentrum, Deutsches Herzzentrum München, an der Technische Universität München, Munich, Germany; Deutsches Zentrum für Herz-Kreislauf-Forschung, Partner Site Munich, Munich, Germany.
  • Department of Cardiology, Universitätsherzzentrum Freiburg Bad Krotzingen, Bad Krotzingen, Germany.
  • Deutsches Zentrum für Herz-Kreislauf-Forschung, Partner Site Munich, Munich, Germany; Erste Medizinische Klinik, Klinikum Rechts der Isar der Technischen Universität München, Munich, Germany.
  • ISAResearch Zentrum, Deutsches Herzzentrum München, an der Technische Universität München, Munich, Germany; Deutsches Zentrum für Herz-Kreislauf-Forschung, Partner Site Munich, Munich, Germany. Electronic address: sebas…

Zitieren

APA

Koch, T., Lenz, T., Rheude, T., Cassese, S., Kazazi, M., Xhepa, E., Kessler, T., Wiebe, J., Ferenc, M., Laugwitz, K. L., Joner, M., Schunkert, H., Kastrati, A., & Kufner, S. (2024). Recurrent Revascularization at 10 Years After Percutaneous Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2023.10.031

Vancouver

Koch T, Lenz T, Rheude T, Cassese S, Kazazi M, Xhepa E, et al. Recurrent Revascularization at 10 Years After Percutaneous Treatment of Drug-Eluting Stent Restenosis. JACC: Cardiovascular Interventions. 2024. doi:10.1016/j.jcin.2023.10.031

BibTeX
@article{Koch2024,
  author = {Koch, Tobias and Lenz, Tobias and Rheude, Tobias and Cassese, Salvatore and Kazazi, Mej and Xhepa, Erion and Kessler, Thorsten and Wiebe, Jens and Ferenc, Miroslaw and Laugwitz, Karl-Ludwig and Joner, Michael and Schunkert, Heribert and Kastrati, Adnan and Kufner, Sebastian},
  title = {Recurrent Revascularization at 10 Years After Percutaneous Treatment of Drug-Eluting Stent Restenosis},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  doi = {10.1016/j.jcin.2023.10.031}
}
Kostenlos starten →